• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    6/14/24 12:31:56 PM ET
    $CNSP
    $CYCN
    $GANX
    $INAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNSP alert in real time by email

    Gainers

    • Cyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 37.4% to $2.9 during Friday's regular session. The market value of their outstanding shares is at $7.2 million.
    • CNS Pharma (NASDAQ:CNSP) stock rose 35.86% to $4.92. The market value of their outstanding shares is at $1.9 million.
    • Longeveron (NASDAQ:LGVN) shares moved upwards by 23.23% to $3.31. The market value of their outstanding shares is at $21.0 million.
    • iSpecimen (NASDAQ:ISPC) stock moved upwards by 19.44% to $0.49. The market value of their outstanding shares is at $4.8 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 17.8% to $3.32. The market value of their outstanding shares is at $1.9 million.
    • Disc Medicine (NASDAQ:IRON) shares increased by 17.59% to $46.05. The company's market cap stands at $1.1 billion.

    Losers

    • Nexalin Technology (NASDAQ:NXL) stock fell 36.2% to $0.88 during Friday's regular session. The company's market cap stands at $6.5 million.
    • Kyverna Therapeutics (NASDAQ:KYTX) shares decreased by 34.46% to $9.46. The market value of their outstanding shares is at $408.0 million.
    • Gain Therapeutics (NASDAQ:GANX) shares fell 32.29% to $1.28. The company's market cap stands at $23.1 million.
    • IN8bio (NASDAQ:INAB) shares declined by 30.06% to $1.18. The company's market cap stands at $51.8 million.
    • Nanoviricides (AMEX:NNVC) shares declined by 25.39% to $1.93. The company's market cap stands at $22.7 million.
    • Rezolute (NASDAQ:RZLT) stock declined by 21.9% to $4.03. The market value of their outstanding shares is at $161.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CNSP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNSP
    $CYCN
    $GANX
    $INAB

    CompanyDatePrice TargetRatingAnalyst
    NanoViricides Inc.
    $NNVC
    12/16/2025Buy
    Alliance Global Partners
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    Disc Medicine Inc.
    $IRON
    11/3/2025$125.00Buy
    Stifel
    Kyverna Therapeutics Inc.
    $KYTX
    8/20/2025Outperform
    William Blair
    Disc Medicine Inc.
    $IRON
    7/21/2025$86.00Buy
    Truist
    Disc Medicine Inc.
    $IRON
    7/3/2025$85.00Overweight
    Morgan Stanley
    More analyst ratings

    $CNSP
    $CYCN
    $GANX
    $INAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Westlake Biopartners Opportunity Fund I, L.P. bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:42:37 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GANX
    $INAB
    SEC Filings

    View All

    SEC Form DEFA14A filed by iSpecimen Inc.

    DEFA14A - iSpecimen Inc. (0001558569) (Filer)

    3/3/26 4:05:22 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form PRE 14A filed by Longeveron Inc.

    PRE 14A - Longeveron Inc. (0001721484) (Filer)

    3/3/26 7:59:59 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    3/2/26 5:00:26 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GANX
    $INAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rezolute to Participate in the Citizens Life Sciences Conference

    REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Citizens representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hy

    3/4/26 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

    The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

    3/3/26 5:31:00 PM ET
    $AMGN
    $IRON
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

    Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical breakthroughs and manufacturing milestones reshaping regenerative medicine[1]. CAR T-cell therapy alone is valued at nearly $7 billion this year, expanding at an 18% compound annual growth rate as off-the-shelf platforms eliminate the logistical barriers that once limited patient access[2]. Among the companies advancing next-generation cell-based treatments are Avaí Bio (OTCQB:AVAI), FibroBiologics (NASDAQ:FBLG), Fate Therapeutics (NASDAQ:FATE), Mesoblast (NASDAQ:MESO), and Longeve

    3/3/26 10:02:00 AM ET
    $FATE
    $FBLG
    $LGVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CNSP
    $CYCN
    $GANX
    $INAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on NanoViricides

    Alliance Global Partners initiated coverage of NanoViricides with a rating of Buy

    12/16/25 8:59:58 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GANX
    $INAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 11,439 shares, decreasing direct ownership by 4% to 296,913 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:18:04 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron covered exercise/tax liability with 11,438 shares, decreasing direct ownership by 3% to 404,462 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:16:14 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Elam Nevan C covered exercise/tax liability with 27,618 shares, decreasing direct ownership by 4% to 613,501 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:07:36 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GANX
    $INAB
    Leadership Updates

    Live Leadership Updates

    View All

    Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

    Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support Kyverna's next phase of growth EMERYVILLE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors. Mr. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped d

    2/24/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GANX
    $INAB
    Financials

    Live finance-specific insights

    View All

    Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

    Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026  Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single dose Miv-cel was generally well-tolerated with no high-grade CRS or ICANS observed SPS is a debilitating, progressive autoimmune disease with no FDA-approved therapies Company to host webcast today, December 15, 2025 at 8 am ET EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a c

    12/15/25 6:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

    EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join th

    12/14/25 2:30:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

    Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self

    12/11/25 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GANX
    $INAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 5:44:55 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 4:33:10 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care